{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T14:11:01Z","timestamp":1653660661542},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:p>This letter to the editor is in response to the letter from Brugu's and colleagues regarding the Warner et al. study of sicca syndrome induced by immune checkpoint inhibitor therapy.<\/jats:p>","DOI":"10.1634\/theoncologist.2019-0515","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:35:18Z","timestamp":1573068918000},"page":"e396-e397","source":"Crossref","is-referenced-by-count":3,"title":["In Reply"],"prefix":"10.1093","volume":"25","author":[{"given":"Blake","family":"Warner","sequence":"first","affiliation":[{"name":"Sj\u00f6gren's Syndrome and Salivary Gland Dysfunction Unit, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Baer","sequence":"additional","affiliation":[{"name":"Sj\u00f6gren's Syndrome and Salivary Gland Dysfunction Unit, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2021122510121763700_R1","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: Optimal management still pending","volume":"25","author":"Ortiz Brugu\u00e9s","year":"2020","journal-title":"The Oncologist"},{"key":"2021122510121763700_R2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"The Oncologist"},{"key":"2021122510121763700_R3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0022034519850564","article-title":"Profiling autoantibodies against salivary proteins in sicca conditions","volume":"98","author":"Burbelo","year":"2019","journal-title":"J Dent Res"},{"key":"2021122510121763700_R4","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122510121763700_R5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510121763700_R6","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"2021122510121763700_R7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0515","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e396\/41919560\/oncolo_25_2_e396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e396\/41919560\/oncolo_25_2_e396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:12:58Z","timestamp":1640427178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/e396\/6443496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,11,6]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0515","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,11,6]]}}}